Fig. 2

a Six-month mean changes in RVMi following treatment with empagliflozin versus placebo. b Six-month mean changes in RVEDVi following treatment with empagliflozin versus placebo. c Six-month mean changes in RVESVi following treatment with empagliflozin versus placebo. d Six-month mean changes in RVEF following treatment with empagliflozin versus placebo. (*) Data analyzed using ANCOVA adjusting for baseline values. RVMi, right ventricular mass index; RVEDVi, right ventricular end diastolic volume index; RVESVi, right ventricular end systolic volume index; RVEF, right ventricular ejection fraction. Baseline and 6-month data were available for 44 individuals in the in the empagliflozin group and 46 in the placebo group. Mean changes in RVMi, RVEDVi, RVESVi and RVEF are presented as mean (95% CI), and the adjusted differences between groups are shown with 95% CI. Data were analyzed using ANCOVA adjusting for baseline values